---
figid: PMC7868523__fonc-10-592202-g001
figlink: pmc/articles/PMC7868523/figure/f1/
number: F1
caption: Molecular Pathogenesis of Thyroid Cancer. RAS/RAF/MEK and PI3K/AKT/mTOR pathways
  are key signaling pathways in thyroid cancer pathogenesis. Mutations in RAS (RASm)
  or BRAF result in constitutive activation of the MAPK pathway, causing downstream
  activation of the MAPK and PI3K pathways which promotes cell growth and tumorigenesis.
  Effective agents include multikinase inhibitors (cabozantinib, vandetanib, sorafenib
  and lenvatinib) which inhibit receptor tyrosine kinases (RTK) at the cell surface,
  selective RET inhibitors (selpercatinib and pralsetinib) which inhibit mutant RET
  RTK (RETm), BRAF V600E inhibitors (dabrafenib and trametinib) and the mTOR inhibitor
  everolimus. These small molecule inhibitors are used clinically for treatment of
  RAIR TC with the goal of arresting uncontrolled proliferation.
pmcid: PMC7868523
papertitle: 'Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies,
  Resistance Mechanisms, and Future Directions.'
reftext: Ashleigh Porter, et al. Front Oncol. 2020;10:592202.
pmc_ranked_result_index: '19379'
pathway_score: 0.9280308
filename: fonc-10-592202-g001.jpg
figtitle: Molecular Pathogenesis of Thyroid Cancer
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7868523__fonc-10-592202-g001.html
  '@type': Dataset
  description: Molecular Pathogenesis of Thyroid Cancer. RAS/RAF/MEK and PI3K/AKT/mTOR
    pathways are key signaling pathways in thyroid cancer pathogenesis. Mutations
    in RAS (RASm) or BRAF result in constitutive activation of the MAPK pathway, causing
    downstream activation of the MAPK and PI3K pathways which promotes cell growth
    and tumorigenesis. Effective agents include multikinase inhibitors (cabozantinib,
    vandetanib, sorafenib and lenvatinib) which inhibit receptor tyrosine kinases
    (RTK) at the cell surface, selective RET inhibitors (selpercatinib and pralsetinib)
    which inhibit mutant RET RTK (RETm), BRAF V600E inhibitors (dabrafenib and trametinib)
    and the mTOR inhibitor everolimus. These small molecule inhibitors are used clinically
    for treatment of RAIR TC with the goal of arresting uncontrolled proliferation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - MAP2K1
  - MAP2K2
  - AKT2
  - AKT3
  - AKT1
  - MTOR
  - MAPK3
  - MAPK1
  - Vandetanib
  - Cabozantinib
  - Sorafenib
  - Lenvatinib
  - Dabrafenib
  - Vemurafenib
  - Everolimus
genes:
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
chemicals:
- word: Vandetanib
  source: MESH
  identifier: C452423
- word: Cabozantinib
  source: MESH
  identifier: C558660
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Lenvatinib
  source: MESH
  identifier: C531958
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Everolimus
  source: MESH
  identifier: C107135
diseases: []
figid_alias: PMC7868523__F1
redirect_from: /figures/PMC7868523__F1
figtype: Figure
---
